PMID- 31481089
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200225
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 14
IP  - 1
DP  - 2019 Sep 3
TI  - Lung Stereotactic Body Radiation Therapy (SBRT) dose gradient and PTV volume: a 
      retrospective multi-center analysis.
PG  - 162
LID - 10.1186/s13014-019-1334-9 [doi]
LID - 162
AB  - BACKGROUND: The treatment of lung lesions with stereotactic body radiation 
      therapy calls for highly conformal dose, which is evaluated by a number of 
      metrics. Lung stereotactic body radiation therapy clinical trials constrain a 
      plans gradient index. The purpose of this work is to describe the dependence of 
      clinically achievable dose gradient on planning target volume. METHODS: Three 
      hundred seventy-four lung stereotactic body radiation therapy treatment plans 
      were retrospectively reviewed and selected for this study. The relationship 
      between R50% and planning target volume size was observed and compared against 
      the RTOG 0915 and 0813 constraints noting minor and major deviations. Then a 
      least squares regression was used to determine the coefficients for a power 
      functional form of the dependence of gradient measure (GM) on planning target 
      volume size. RESULTS: Of the 317 peripheral lung SBRT plans, 142 exhibited no 
      deviation, 135 exhibited a minor deviation, and 40 exhibited a major deviation 
      according to the RTOG 0915 dosimetric. conformality and dose fall-off 
      constraints. A plot of gradient measure versus planning target volume size for 
      peripheral lesions, excluding RTOG 0915 major deviations, is fit with an power 
      function of GM = 0.564 V(0.215). CONCLUSIONS: Using the PTV size and GM 
      relationship we have characterized, treatment plans with PTV < 85 cm(3) can be 
      evaluated subjectively to our previously plans, and given a percentile GM. This 
      relationship and evaluation is useful for volumetric modulated arc therapy lung 
      stereotactic body radiation therapy treatment planning and quality control.
FAU - Hoffman, David
AU  - Hoffman D
AD  - UC San Diego Radiation Medicine and Applied Sciences, 3855 Health Sciences Dr. 
      #0843, La Jolla, CA, 92093-0843, USA.
FAU - Dragojevic, Irena
AU  - Dragojevic I
AD  - UC San Diego Radiation Medicine and Applied Sciences, 3855 Health Sciences Dr. 
      #0843, La Jolla, CA, 92093-0843, USA.
FAU - Hoisak, Jeremy
AU  - Hoisak J
AD  - UC San Diego Radiation Medicine and Applied Sciences, 3855 Health Sciences Dr. 
      #0843, La Jolla, CA, 92093-0843, USA.
FAU - Hoopes, David
AU  - Hoopes D
AD  - UC San Diego Radiation Medicine and Applied Sciences, 3855 Health Sciences Dr. 
      #0843, La Jolla, CA, 92093-0843, USA.
FAU - Manger, Ryan
AU  - Manger R
AUID- ORCID: 0000-0002-1914-7534
AD  - UC San Diego Radiation Medicine and Applied Sciences, 3855 Health Sciences Dr. 
      #0843, La Jolla, CA, 92093-0843, USA. rmanger@ucsd.edu.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190903
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Humans
MH  - Lung Neoplasms/*pathology/*surgery
MH  - Organs at Risk/radiation effects
MH  - Prognosis
MH  - Radiosurgery/*methods
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Radiotherapy, Intensity-Modulated/methods
MH  - Retrospective Studies
MH  - Tumor Burden
PMC - PMC6724320
OTO - NOTNLM
OT  - Gradient index
OT  - Gradient measure
OT  - Lung cancer
OT  - Radiotherapy
OT  - Retrospective
OT  - SBRT
COIS- The authors declare that they have no competing interests.
EDAT- 2019/09/05 06:00
MHDA- 2020/02/15 06:00
PMCR- 2019/09/03
CRDT- 2019/09/05 06:00
PHST- 2019/01/28 00:00 [received]
PHST- 2019/07/09 00:00 [accepted]
PHST- 2019/09/05 06:00 [entrez]
PHST- 2019/09/05 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/09/03 00:00 [pmc-release]
AID - 10.1186/s13014-019-1334-9 [pii]
AID - 1334 [pii]
AID - 10.1186/s13014-019-1334-9 [doi]
PST - epublish
SO  - Radiat Oncol. 2019 Sep 3;14(1):162. doi: 10.1186/s13014-019-1334-9.